11,12,15-trihydroxyeicosatrienoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

11,12,15-trihydroxyeicosatrienoic acid (11,12,15-THETA) is a bioactive lipid, a type of **hydroxy fatty acid**, derived from the metabolism of arachidonic acid by the enzyme **cytochrome P450**. It plays a crucial role in various physiological and pathological processes.

**Why is it important for research?**

1. **Inflammatory response:** 11,12,15-THETA is a potent **pro-inflammatory mediator**. It contributes to inflammation by activating various signaling pathways, including the nuclear factor kappa B (NF-κB) pathway. Research focuses on understanding its role in inflammatory diseases like arthritis, asthma, and inflammatory bowel disease.

2. **Cardiovascular health:** Studies suggest that 11,12,15-THETA can influence cardiovascular function. It has been linked to **vasoconstriction** and **platelet aggregation**, which could contribute to the development of atherosclerosis and other cardiovascular diseases.

3. **Neuroprotection:** Some research suggests that 11,12,15-THETA might have **neuroprotective effects**. It has been shown to inhibit the production of reactive oxygen species (ROS) and protect neurons from damage. However, more research is needed to confirm these findings.

4. **Cancer research:** Research into the role of 11,12,15-THETA in cancer is ongoing. Some studies suggest it may be involved in **tumor growth and metastasis**. Further research is needed to elucidate its specific role and potential as a therapeutic target.

5. **Drug development:** Due to its significant biological activity, 11,12,15-THETA is a promising target for developing new drugs. Research focuses on developing **inhibitors or modulators** of 11,12,15-THETA synthesis or its signaling pathways to treat inflammatory, cardiovascular, and neurodegenerative diseases.

**Overall, 11,12,15-THETA is a fascinating molecule with diverse biological roles. Continued research is crucial for understanding its exact functions, interactions with other molecules, and potential therapeutic applications.**

11,12,15-trihydroxyeicosatrienoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6439610
SCHEMBL ID	9301740
SCHEMBL ID	9301742
MeSH ID	M0181382

Synonyms (9)

Synonym
(5e,8e,13e)-11,12,15-trihydroxyicosa-5,8,13-trienoic acid
11,12,15-trihydroxy-5,8,13-eicosatrienoic acid
5,8,13-eicosatrienoic acid, 11,12,15-trihydroxy-
11,12,15-teta
11,12,15-trihydroxyeicosatrienoic acid
82144-59-0
SCHEMBL9301740
SCHEMBL9301742
11,12,15-trihydroxyeicosatrienoate

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (20.00)	18.2507
2000's	8 (80.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.42 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.82 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.42)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	1.99	1	dichlorobenzene; ether; imidazoles
allyl alcohol allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.	2.03	1	primary allylic alcohol; propenol	antibacterial agent; fungicide; herbicide; insecticide; plant metabolite
carbonates Carbonates: Salts or ions of the theoretical carbonic acid, containing the radical CO2(3-). Carbonates are readily decomposed by acids. The carbonates of the alkali metals are water-soluble; all others are insoluble. (From Grant & Hackh's Chemical Dictionary, 5th ed). carbonates : Organooxygen compounds that are salts or esters of carbonic acid, H2CO3.	2.03	1	carbon oxoanion
nitroarginine Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.	2.01	1	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	3.28	6	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	1.97	1	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	4.82	10	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
15-hydroxy-5,8,11,13-eicosatetraenoic acid 15-hydroxy-5,8,11,13-eicosatetraenoic acid: potent & selective inhibitor of platelet lipoxygenase; RN given refers to cpd without isomeric designation	2.03	1
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid: RN given refers to cpd without isomeric designation; (S-(E,Z,Z,Z))-isomer caused dose-dependent constriction of cat coronary arteries; structure in first source. 15-HPETE : A HPETE that consists of (5Z,8Z,11Z,13E)-icosatetraenoic acid in which the hydroperoxy group is located at position 15.	2.39	2	HPETE	human xenobiotic metabolite
lipoxin a5 lipoxin A5: structure given in first source; RN given refers to (5S-(5R,6R,7E,9E,13E,15R*,17Z)-isomer	1.97	1	HEPE

Condition	Relationship Strength	Studies
Elevated Cholesterol [description not available]	2.04	1
Blood Pressure, Low [description not available]	2.04	1
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	2.04	1
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	2.04	1
Anoxemia [description not available]	2.05	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.05	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.05	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.04	1
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.44	2

chemdatabank.com